Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.

IF 1.7 4区医学 Q2 SURGERY

Minimally Invasive Therapy & Allied Technologies Pub Date : 2023-12-01 Epub Date: 2023-08-22 DOI:10.1080/13645706.2023.2249986

Naotaka Kumada, Keita Nakane, Toyohiro Yamada, Risa Tomioka-Inagawa, Fumiya Sugino, Sanae Namiki, Makoto Kawase, Kota Kawase, Shinichi Takeuchi, Chie Nakai, Daiki Kato, Manabu Takai, Koji Iinuma, Yuki Tobisawa, Takuya Koie

{"title":"Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.","authors":"Naotaka Kumada, Keita Nakane, Toyohiro Yamada, Risa Tomioka-Inagawa, Fumiya Sugino, Sanae Namiki, Makoto Kawase, Kota Kawase, Shinichi Takeuchi, Chie Nakai, Daiki Kato, Manabu Takai, Koji Iinuma, Yuki Tobisawa, Takuya Koie","doi":"10.1080/13645706.2023.2249986","DOIUrl":null,"url":null,"abstract":"Introduction: This study aimed to investigate the efficacy and safety of robot-assisted radical cystectomy (RARC) in older patients with bladder cancer (BCa).Material and methods: We reviewed the clinical and pathological records of 110 patients with BCa who underwent RARC at Gifu University Hospital between February 2019 and January 2023. Older patients were defined as those with BCa aged ≥ 75 years. The enrolled patients were divided into two groups: those aged < 75 years (Group I) and those aged ≥ 75 years (Group II). Oncological outcomes, including overall survival (OS) and recurrence-free survival (RFS), were the primary endpoints of the study; the secondary endpoints were the surgical and pathological outcomes.Results: A shorter console time, less blood loss, and reduced time to postoperative fluid and food intake in Group II may be attributed to the fact that more patients opted for ureterocutaneostomy in Group II than in Group I. In all patients, the three-year OS and RFS rates were 84.7% and 88.5%, respectively. There were no significant differences in OS or RFS between the two groups. (p = .403, p = .963, respectively).Conclusions: RARC appears to be a safe and useful treatment option for older patients with BCa.","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"307-313"},"PeriodicalIF":1.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2023.2249986","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aimed to investigate the efficacy and safety of robot-assisted radical cystectomy (RARC) in older patients with bladder cancer (BCa).Material and methods: We reviewed the clinical and pathological records of 110 patients with BCa who underwent RARC at Gifu University Hospital between February 2019 and January 2023. Older patients were defined as those with BCa aged ≥ 75 years. The enrolled patients were divided into two groups: those aged < 75 years (Group I) and those aged ≥ 75 years (Group II). Oncological outcomes, including overall survival (OS) and recurrence-free survival (RFS), were the primary endpoints of the study; the secondary endpoints were the surgical and pathological outcomes.Results: A shorter console time, less blood loss, and reduced time to postoperative fluid and food intake in Group II may be attributed to the fact that more patients opted for ureterocutaneostomy in Group II than in Group I. In all patients, the three-year OS and RFS rates were 84.7% and 88.5%, respectively. There were no significant differences in OS or RFS between the two groups. (p = .403, p = .963, respectively).Conclusions: RARC appears to be a safe and useful treatment option for older patients with BCa.

查看原文本刊更多论文

老年膀胱癌患者接受机器人辅助根治性膀胱切除术的实用性和安全性。

简介：本研究旨在探讨老年膀胱癌患者接受机器人辅助根治性膀胱切除术（RARC）的有效性和安全性：本研究旨在探讨机器人辅助根治性膀胱切除术（RARC）对老年膀胱癌（BCa）患者的有效性和安全性：我们回顾了2019年2月至2023年1月期间在岐阜大学医院接受RARC手术的110例膀胱癌患者的临床和病理记录。老年患者定义为年龄≥ 75 岁的 BCa 患者。入组患者分为两组：年龄<75岁（I组）和年龄≥75岁（II组）。研究的主要终点是肿瘤学结果，包括总生存期（OS）和无复发生存期（RFS）；次要终点是手术和病理学结果：第二组的控制台时间更短、失血量更少、术后摄入液体和食物的时间更短，这可能是因为第二组选择输尿管造口术的患者多于第一组。两组患者的 OS 和 RFS 无明显差异。(P=0.403，P=0.963）：RARC似乎是老年BCa患者一种安全有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minimally Invasive Therapy & Allied Technologies 医学-外科

CiteScore

3.80

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.